Scholarlink

Background <p>Adverse events during postoperative adjuvant chemotherapy may reflect prognosis in resectable advanced colorectal cancer. This study assessed the association between these events and survival in advanced colorectal cancer patients.</p> Methods <p>We analysed patient data from four Japanese randomised controlled trials on adjuvant chemotherapy for stage II or III colorectal cancer. Adverse events were defined as the maximum grade within 6 months. The primary outcome was overall survival, analysed using a multivariate-adjusted Cox proportional hazard model.</p> Results <p>A total of 4,046 patients with advanced colorectal cancer undergoing adjuvant chemotherapy were included. Maximum adverse event grades were: 739 (18%) grade 0, 960 (24%) grade 1, 1511 (37%) grade 2, 779 (19%) grade 3 and 57 (1.4%) grade 4. Compared to grade 0, hazard ratios for overall survival were 0.77 (95% CI, 0.61–0.98) for grade 1, 0.70 (95% CI, 0.56–0.87) for grade 2, 0.69 (95% CI, 0.53–0.91) for grade 3 and 1.12 (95% CI, 0.62–2.04) for grade 4.</p> Conclusions <p>The severity of adverse events during adjuvant chemotherapy correlated with survival outcomes in advanced colorectal cancer. Mild to moderate events were linked to improved prognosis, while absence suggested poorer outcomes, indicating a need for alternative treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月22日

查看全文
  • Hidetaka Kawamura,
  • Michitaka Honda,
  • Yujiro Nakayama,
  • Koji Oba,
  • Masaru Muto,
  • Toru Aoyama,
  • Mitsuro Kanda,
  • Hiromichi Maeda,
  • Shuhei Mayanagi,
  • Kosuke Kashiwabara,
  • Kenji Tanaka,
  • Junichi Sakamoto,
  • Hisakazu Yamagishi,
  • Takaki Yoshikawa

摘要

Background

Adverse events during postoperative adjuvant chemotherapy may reflect prognosis in resectable advanced colorectal cancer. This study assessed the association between these events and survival in advanced colorectal cancer patients.

Methods

We analysed patient data from four Japanese randomised controlled trials on adjuvant chemotherapy for stage II or III colorectal cancer. Adverse events were defined as the maximum grade within 6 months. The primary outcome was overall survival, analysed using a multivariate-adjusted Cox proportional hazard model.

Results

A total of 4,046 patients with advanced colorectal cancer undergoing adjuvant chemotherapy were included. Maximum adverse event grades were: 739 (18%) grade 0, 960 (24%) grade 1, 1511 (37%) grade 2, 779 (19%) grade 3 and 57 (1.4%) grade 4. Compared to grade 0, hazard ratios for overall survival were 0.77 (95% CI, 0.61–0.98) for grade 1, 0.70 (95% CI, 0.56–0.87) for grade 2, 0.69 (95% CI, 0.53–0.91) for grade 3 and 1.12 (95% CI, 0.62–2.04) for grade 4.

Conclusions

The severity of adverse events during adjuvant chemotherapy correlated with survival outcomes in advanced colorectal cancer. Mild to moderate events were linked to improved prognosis, while absence suggested poorer outcomes, indicating a need for alternative treatments.